Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2018 - 2026)
Fulcrum Therapeutics (FULC) reported Other Non-Current Liabilities of $197000.0 for Q1 2026, little changed year-over-year from $197000.0 in Q1 2025, and little changed quarter-over-quarter from $197000.0 in Q4 2025.
Fulcrum Therapeutics (FULC) Other Non-Current Liabilities (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has 8 years of Other Non-Current Liabilities data on file, last reported at $197000.0 in Q1 2026.
- Other Non-Current Liabilities for Q1 2026 came in at $197000.0, changed 0.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $197000.0 (changed 0.0% YoY), and the FY2025 annual result was $197000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities was little changed at $197000.0 in Q1 2026 per FULC's latest filing, from $197000.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $447000.0 in Q2 2023 and troughed at $197000.0 in Q2 2022.
- A 5-year average of $220312.5 and a median of $197000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities surged 126.9% in 2023, then tumbled 55.93% in 2024.
- A 5-year view of Other Non-Current Liabilities shows it stood at $197000.0 in 2022, then changed by 0.0% to $197000.0 in 2023, then changed by 0.0% to $197000.0 in 2024, then changed by 0.0% to $197000.0 in 2025, then changed by 0.0% to $197000.0 in 2026.
- Business Quant data shows FULC's Other Non-Current Liabilities at $197000.0 in Q1 2026, $197000.0 in Q4 2025, and $197000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 197,000.00 |
| Dec 31, 2025 | 197,000.00 |
| Sep 30, 2025 | 197,000.00 |
| Jun 30, 2025 | 197,000.00 |
| Mar 31, 2025 | 197,000.00 |
| Dec 31, 2024 | 197,000.00 |
| Sep 30, 2024 | 197,000.00 |
| Jun 30, 2024 | 197,000.00 |
| Mar 31, 2024 | 197,000.00 |
| Dec 31, 2023 | 197,000.00 |
| Sep 30, 2023 | 197,000.00 |
| Jun 30, 2023 | 447,000.00 |
| Mar 31, 2023 | 320,000.00 |
| Dec 31, 2022 | 197,000.00 |
| Sep 30, 2022 | 197,000.00 |
| Jun 30, 2022 | 197,000.00 |
| Sep 30, 2020 | 7,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | 31,000.00 |
| Dec 31, 2019 | 55,000.00 |